Endothelial dysfunction is associated with increased levels of biomarkers in essential hypertension

Journal of Human Hypertension

Volumn 24, Issue 6, 2010, Pages 373-379

  De La Sierra, A ^a   Larrousse, M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Chemokines; Endothelium; Matrix metalloproteinases; Oxidative stress; Selectins; Vascular

Indexed keywords

ACETYLCHOLINE; ALPHA TOCOPHEROL; ASCORBIC ACID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CHEMOKINE; COPPER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE A; GELATINASE B; GLUTATHIONE PEROXIDASE; HOMOCYSTEINE; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MALONALDEHYDE; METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; RETINOL; SELECTIN; SELENIUM; SUPEROXIDE DISMUTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULAR CELL ADHESION MOLECULE 1; ZINC;

ADULT; ANGIOGENESIS; ARTICLE; BLOOD ANALYSIS; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE MARKER; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE; ESSENTIAL HYPERTENSION; FEMALE; FOREARM BLOOD FLOW; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PROGNOSIS; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; VASODILATATION;

ACETYLCHOLINE; ADULT; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; CHEMOKINES; COPPER; ENDOTHELIUM, VASCULAR; FEMALE; GLUTATHIONE PEROXIDASE; HOMOCYSTEINE; HUMANS; HYPERTENSION; MALE; MALONDIALDEHYDE; METALLOPROTEASES; MIDDLE AGED; OXIDATIVE STRESS; RISK FACTORS; SELECTINS; SELENIUM; SUPEROXIDE DISMUTASE; VASCULITIS; VASODILATION; VITAMINS; ZINC;

EID: 77952423444     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.91     Document Type: Article

References (33)

1. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993;87:1468-1474.
2. Panza JA, García CE, Kilcoyne CM, Quyyumi AA, Cannon 3rd RO. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 1995;91:1732-1738.
3. Giannotti G, Landmesser U. Endothelial dysfunction as an early sign of atherosclerosis. Herz 2007;32:568-572.
4. Landmesser U, Drexler H. The clinical significance of endothelial dysfunction. Curr Opin Cardiol 2005;20:547-551.
5. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001;104:191-196.
6. Bragulat E, de la Sierra A, Antonio MT, Coca A. Endothelial dysfunction in salt-sensitive essential hypertension. Hypertension 2001;37:444-448.
7. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-1906.
8. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000;101:1653-1659.
9. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126.
10. Halcox JPJ, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653-658.
11. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Münzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-2678.
12. Ashfaq S, Abramson JL, Jones DP, Rhodes SD, Weintraub WS, Hooper WC et al. Endothelial function and aminothiol biomarkers of oxidative stress in healthy adults. Hypertension 2008;52:80-85.
13. DeSouza CA, Dengel DR, Macko RF, Cox K, Seals DR. Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens 1997;10:1335-1341. (Pubitemid 28078736)
14. Preston RA, Ledford M, Materson BJ, Baltodano NM, Memon A, Alonso A. Effects of severe, uncontrolled hypertension on endothelial activation: soluble vascular cell adhesion molecule-1, soluble intercellular adhesion molecule-1 and von Willebrand factor. J Hypertens 2002;20:871-877.
15. Laviades C, Varo N, Fernández J, Mayor G, Gil MJ, Monreal I et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998;98:535-540.
16. Zervoudaki A, Economou E, Stefanadis C, Pitsavos C, Tsioufis K, Aggeli C et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Human Hypertens 2003;17:119-124.
17. De Caterina R, Ghiadoni L, Taddei S, Virdis A, Almerigogna F, Basta G et al. Soluble e-selectin in essential hypertension: a correlate of vascular structural changes. Am J Hypertens 2001;14:259-266.
18. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004;291:1978-1986.
19. Kuroda YT, Komamura K, Tatsumi R, Mori K, Yoneda K, Katayama Y et al. Vascular cell adhesion molecule-1 as a biochemical marker of left ventricular mass in the patients with hypertension. Am J Hypertens 2001;14:868-872.
20. Timms PM, Wright A, Maxwell P, Campbell S, Dawnay AB, Srikanthan V. Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy. Am J Hypertens 2002;15:269-272.
21. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001;104:1336-1342.
22. De Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003;107:690-695.
23. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-1585.
24. Bragulat E, Larrousse M, Coca A, de la Sierra A. Effect of long-term irbesartan treatment on endotheliumdependent vasodilation in essential hypertensive patients. Br J Biomed Sci 2003;60:191-196.
25. Larrousse M, Bragulat E, Sagarra M, Sierra C, Coca A, de la Sierra A. Increased levels of atherosclerosis markers in salt-sensitive hypertension. Am J Hypertens 2006;19:87-93.
26. Muiesan ML, Salvetti M, Paini A, Monteduro C, Galbassini G, Poisa P et al. Prognostic role of flow-mediated dilatation of the brachial artery in hypertensive patients. J Hypertens 2008;26:1612-1618.
27. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases. The role of oxidant stress. Circ Res 2000;87:840-844.
28. Blann AD, Nadar SK, Lip GYH. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003;24:2166-2179.
29. Roldan V, Marin F, Lip GYH, Blann AD. Soluble E-selectin in cardiovascular disease and its risk factors. Thromb Haemost 2003;90:1007-1020.
30. Egashira K. Molecular mechanisms mediating inflammation in vascular disease. Special reference to monocyte chemoattractant protein-1. Hypertension 2003;41:834-841.
31. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001;103:491-495.
32. Ward NC, Croft KD. Hypertension and oxidative stress. Clin Exp Pharmacol Physiol 2006;33:872-876.
33. Grossman E. Does increased oxidative stress cause hypertension? Diabetes Care 2008;31(Suppl 2): S185-S189.